Alector to Participate in Upcoming Healthcare Conferences
Rhea-AI Summary
Alector (NASDAQ: ALEC), a late-stage clinical biotechnology company specializing in neurodegeneration therapies, has announced its participation in three upcoming healthcare investor conferences in September 2025.
The company will present at the Cantor Global Healthcare Conference on September 4 at 3:55 p.m. ET, the Morgan Stanley Global Healthcare Conference on September 8 at 10:00 a.m. ET, and the H.C. Wainwright Global Investment Conference on September 9 at 1:30 p.m. ET. All presentations will be available via webcast on Alector's investor relations website, with replays accessible for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction 2 Alerts
On the day this news was published, ALEC declined 0.42%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $254M at that time.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences:
- Cantor Global Healthcare Conference 2025 (New York, New York)
- Thursday, September 4, 2025, at 3:55 p.m. ET, fireside chat
- Morgan Stanley 23rd Annual Global Healthcare Conference (New York, New York)
- Monday, September 8, 2025, at 10:00 a.m. ET, fireside chat
- H.C. Wainwright 27th Annual Global Investment Conference (New York, New York)
- Tuesday, September 9, 2025, at 1:30 p.m. ET, company presentation
A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.
About Alector
Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer’s disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.
Alector Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com
Argot Partners (media)
David Rosen
646-461-6387
alector@argotpartners.com
Argot Partners (investors)
Laura Perry
212-600-1902
alector@argotpartners.com
FAQ
When is Alector (ALEC) presenting at the Cantor Global Healthcare Conference 2025?
How can investors access Alector's (ALEC) healthcare conference presentations?
Which investor conferences is Alector (ALEC) attending in September 2025?
What type of company is Alector (ALEC)?
